Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dyslipidemia

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 11 articles:
HTML format
Text format



Single Articles


    March 2017
  1. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    PubMed     Text format     Abstract available


    November 2016
  2. RERUP SA, Bang LE, Mogensen UM, Engstrom T, et al
    The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction.
    Am Heart J. 2016;181:35-42.
    PubMed     Text format     Abstract available


    August 2016
  3. RIDKER PM, Amarenco P, Brunell R, Glynn RJ, et al
    Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Eve
    Am Heart J. 2016;178:135-44.
    PubMed     Text format     Abstract available


    February 2016
  4. SEBBEN JC, Pinto Ribeiro DR, Lopes RD, de Winter R, et al
    The role of diabetes mellitus in the composition of coronary thrombi in patients presenting with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Am Heart J. 2016;172:26-33.
    PubMed     Text format     Abstract available


    December 2015
  5. DASARI TW, Saucedo JF, Krim S, Alkhouli M, et al
    Clinical characteristics and in hospital outcomes of heart transplant recipients with allograft vasculopathy undergoing percutaneous coronary intervention: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2015;170:1086-91.
    PubMed     Text format     Abstract available


    October 2015
  6. WEIJMANS M, van der Graaf Y, de Borst GJ, Asselbergs FW, et al
    The relation between the presence of cardiovascular disease and vascular risk factors in offspring and the occurrence of new vascular events in their parents already at high vascular risk.
    Am Heart J. 2015;170:744-752.
    PubMed     Text format     Abstract available


    September 2015
  7. KO MJ, Kim YJ, Park CM, Lee SM, et al
    Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular events.
    Am Heart J. 2015;170:598-605.
    PubMed     Text format     Abstract available


    August 2015
  8. HUNG RK, Al-Mallah MH, Qadi MA, Shaya GE, et al
    Cardiorespiratory fitness attenuates risk for major adverse cardiac events in hyperlipidemic men and women independent of statin therapy: The Henry Ford ExercIse Testing Project.
    Am Heart J. 2015;170:390-9.
    PubMed     Text format     Abstract available


    June 2015
  9. EREZ A, Kivity S, Berkovitch A, Milwidsky A, et al
    The association between cardiorespiratory fitness and cardiovascular risk may be modulated by known cardiovascular risk factors.
    Am Heart J. 2015;169:916-923.
    PubMed     Text format     Abstract available


  10. KEREIAKES DJ, Robinson JG, Cannon CP, Lorenzato C, et al
    Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
    Am Heart J. 2015;169:906-915.
    PubMed     Text format     Abstract available


    May 2015
  11. HOVINGH GK, Smits LP, Stefanutti C, Soran H, et al
    The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study.
    Am Heart J. 2015;169:736-742.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: